Mark D. Sternlicht

机构：FibroGen (United States) · ORCID：0000-0002-3644-3861

发表论文 97 篇 · 总被引 9431 次 · h-index 30

代表论文

• Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer (2017 · Hypoxia · 被引 53)
• Radiation-induced pulmonary gene expression changes are attenuated by the CTGF antibody Pamrevlumab (2018 · Respiratory Research · 被引 28)
• Prognostic utility of inflammation biomarkers in a PDAC trial involving the human anti-CTGF antibody pamrevlumab. (2020 · Journal of Clinical Oncology · 被引 2)
• Discovery of Novel, Potent, Orally Bioavailable and Efficacious, Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for Hematopoietic Stem Cell Mobilization (2025 · Journal of Medicinal Chemistry · 被引 1)
• 1333 FG-3165 is a novel galectin-9 neutralizing antibody that inhibits galectin-9-mediated dimerization of TIM-3 and galectin-9-induced apoptosis of CD4+ and CD8+ T cells (2023 · Regular and Young Investigator Award Abstracts · 被引 1)
• Supplementary Materials and Methods from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression (2023)